Magurol (Doxazosin)

Doxazosin blocks alpha‑1 adrenergic receptors on blood vessels and prostatic smooth muscle. This inhibition prevents norepinephrine‑induced constriction, leading to vessel dilation and reduced peripheral resistance, while also relaxing the prostate and bladder neck to improve urine flow.

The appropriate dose of Magurol is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of doxazosin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Magurol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective alpha blockers, doxazosin offers more targeted alpha‑1 antagonism, resulting in fewer reflex tachycardia events. It is often chosen for patients who also need relief of BPH symptoms, whereas other classes such as ACE inhibitors or calcium channel blockers focus solely on blood pressure control.

Magurol should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme heat to maintain its stability and potency throughout its shelf life.

Magurol is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

The most serious risks include severe hypotension leading to fainting, rapid heart rate or arrhythmias, and rare allergic reactions such as rash, swelling or anaphylaxis. Patients should seek immediate medical attention if they experience these symptoms.

Magurol is contraindicated in patients with known hypersensitivity to doxazosin or any component of the formulation, and it should be used with caution in individuals with severe liver disease, uncontrolled heart failure, or those taking interacting medications that could cause dangerous blood‑pressure drops.